Pharmaceutical and biotech companies
Sustainable in the long term
Because nothing is more constant than change: The pharmaceutical and biotech industry faces major challenges
We guarantee sustainable and profitable growth
The healthcare industry is more challenging than ever: pharmaceutical and biotech companies not only have to develop therapeutic innovations, but also meet increasing expectations for the long-term financial viability of medical-technical progress. Only those who have well-filled product pipelines, bring innovations to market maturity and ultimately convince therapy decision-makers, users and payers of the added value are successful. It is precisely this increasing competitive pressure, ever-increasing costs for research and development, extensive and constantly changing framework conditions for market access and pricing & reimbursement as well as digital progress that require innovative strategies.
In addition, the COVID-19 pandemic has put established sales and communication methods in the industry to the test, forcing pharmaceutical and biotech companies to adopt more digitally supported approaches.
In order to remain competitive in the future, companies must increasingly think “out of the box” and – beyond the mere supply of medicines – develop offers with added value for their various stakeholder groups. The opportunities that digitalization brings with it must be recognized, utilized and adequately implemented – in the form of useful products and services for patients, doctors, hospitals and other service providers.
Our team consists of top-class medical professionals, life scientists, pharmacists, (health) economists and health managers and combines many years of consulting expertise for pharmaceutical and biotech clients. What sets us apart is entrepreneurial thinking and excellent connections to relevant decision-makers in the healthcare industry – throughout the German-speaking region (Germany, Austria, Switzerland) and beyond. Establishing our customers sustainably and successfully in their relevant market is our strength.
Current Challenges
Increasing regulation and higher requirements for proving therapeutic benefits make it more difficult for new drugs and therapies to enter the market. The rising cost pressure in the healthcare industry means that reaching an agreement with payers on a reimbursement price for new, innovative therapeutic approaches is becoming increasingly difficult. Those who want to bring new products to market must involve more and more stakeholders at national and regional levels in the discussion.
Global market access strategies must be adapted to national frameworks. Product positioning and marketing are only successful if user-oriented arguments that demonstrate product value and positively impact the reimbursement price are disseminated early on.
Our Solutions
We identify and evaluate regulatory frameworks for market access and reimbursement of innovative therapies, diagnostics, and services. We create market access and pricing strategies – based on product benefits, competitive landscape, and country-specific requirements. And we develop AMNOG strategies and value stories for price negotiations.
Our experienced team also provides support in regional market access topics and navigating the AMNOG process. For market launches and sales, we develop concepts for implementing digital products and services as complementary components of new treatment approaches.
Go-to-market-Consulting
Consulting on market access, pricing & reimbursement, stakeholder management and sales
Communication concepts
Development of communication concepts and content for relevant stakeholder groups within the market access process
Sales support
Development of innovative sales strategies considering “beyond the pill” offerings for inpatient and outpatient sectors
Your contact person
Prof. Dr. Christian Wallwiener
Phone: +49 (0) 89 26 20 84 0 | Email: kontakt@wmc-healthcare.de